AbbVie’s ABBV-453 Study: A New Hope for Multiple Myeloma Treatment

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 1/2 study titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma. The study aims to assess the safety and efficacy of the investigational drug ABBV-453, alone or in combination with other antimyeloma agents, in adult patients with relapsed/refractory multiple myeloma (MM). This research is significant as it addresses a critical need for new treatments in MM, a disease characterized by the growth of clonal plasma cells in the bone marrow.

The study tests oral ABBV-453, a BCL-2 inhibitor, both as a monotherapy and in combination with subcutaneous daratumumab and oral dexamethasone, with or without pomalidomide. These interventions aim to determine the optimal dosing and efficacy of ABBV-453 in treating MM.

This interventional study is randomized and follows a sequential intervention model with no masking, primarily focusing on treatment. It involves a dose escalation phase to identify the best dose of ABBV-453, followed by a dose expansion and selection phase.

The study began on July 23, 2025, with an estimated duration of 4.5 years. The primary completion and estimated overall completion dates are yet to be announced. The last update was submitted on August 11, 2025, indicating the study is actively recruiting participants.

For investors, this study could have significant implications for AbbVie’s stock performance, as successful results may enhance the company’s position in the competitive multiple myeloma treatment market. The study’s progress and outcomes could influence investor sentiment, especially in comparison to competitors developing similar therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.